Post-earnings recap
Reported
Thu, Apr 30, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a smaller-than-expected loss per share, which is a positive surprise. However, the stock fell by over 8% in reaction, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance without clearer direction from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +96.67% |
| Revenue | N/A | N/A | N/A |
Management maintained a neutral tone during the call, focusing on strategic initiatives. They did not provide specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company expressed a commitment to its long-term growth strategy.